Exploratory research of therapeutic agents for neurodegenerative diseases based on clearance of alpha-synuclein
Project/Area Number |
16H07341
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Pharmacology in pharmacy
|
Research Institution | Ritsumeikan University |
Principal Investigator |
|
Project Period (FY) |
2016-08-26 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | α-シヌクレイン / DJ-1 / 神経細胞 / ミクログリア / NF-κB / オートファジー / タンパク質分解系 / ファゴサイトーシス |
Outline of Final Research Achievements |
Preceding studies showed that α-synuclein (α-syn) was accumulated in neurons and extracellular α-syn bound to microglia and caused inflammation in the brain of patients with synucleinopathy. In this study, I investigated the effects of DJ-1 which is one of the causative genes of Parkinson's disease to cell responses induced by α-syn. I revealed that intracellular aggregation of α-syn was increased in the DJ-1 deficient SH-SY5Y cells compared with WT cells. Furthermore, I found that compounds predicted to bind to DJ-1 attenuated the inflammatory response in Microglia. These data suggest that DJ-1 can be a therapeutic target for neurodegenerative disease caused by α-syn.
|
Report
(3 results)
Research Products
(4 results)